Table I.
Patient demographics and baseline disease characteristics (n = 16)
| Characteristic | Value |
|---|---|
| Median age, years (range) | 61·5 (41–75) |
| Male, n (%) | 13 (81) |
| Stage at relapse, n (%) | |
| Stage I,II | 6 (38) |
| Stage III | 3 (19) |
| Stage IV | 7 (44) |
| GCB vs non-GCB subtype, n (%) | 5 (31)/11 (69) |
| Relapse IPI, n (%) | |
| Low, low–intermediate | 8 (50) |
| High–intermediate, high | 8 (50) |
| Primary refractory, n (%) | 7 (44) |
| Relapse occurred <12 months after initial therapy | 7 (44) |
| Relapse occurred >12 months after initial therapy | 2 (13) |
| Initial therapy, n (%) | |
| R-CHOP | 12 (75) |
| R-HCVAD | 3 (19) |
| R-CODOX-M/IVAC | 1 (6) |
GCB, germinal B-cell; IPI, International Prognostic Index; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-HCVAD, rituximab, fractionated cyclophosphamide, vincristine, Adriamycin (doxorubicin), dexamethasone; R-CODOX-M/IVAC, rituximab, cyclophosphamide, doxorubicin, vincristine, methotrexate/etoposide, ifosfamide, cytarabine.